Use of NF-κB inhibition in combination therapy for cancer
First Claim
Patent Images
1. A method of enhancing the cytotoxic effects of an antineoplastic chemotherapeutic agent, comprising administering to a mammalian subject in need of said antineoplastic chemotherapeutic agent a therapeutically effective amount of Nuclear Factor-kappa B (NF-κ
- B) inhibitor in conjunction with the administration of a dosage of the chemotherapeutic agent, whereby the cytotoxic effect of said antineoplastic chemotherapeutic agent is increased compared to that which would occur in the absence of NF-κ
B inhibitor;
wherein the dosage of said antineoplastic chemotherapeutic agent is decreased as compared to a dosage effective without administering the NF-κ
B inhibitor in conjunction with the administration of the chemotherapeutic agent,and wherein said subject is afflicted with lung, breast, prostate, brain, kidney, liver, spleen, pancreas, bone or muscle cancer, leukemia or lymphoma, a sarcoma, a carcinoma or a mixed tumor.
2 Assignments
0 Petitions
Accused Products
Abstract
The use of NF-κB inhibitors to enhance the cytotoxic effects of chemotherapy or radiation therapy in the treatment of neoplastic conditions is described.
8 Citations
22 Claims
-
1. A method of enhancing the cytotoxic effects of an antineoplastic chemotherapeutic agent, comprising administering to a mammalian subject in need of said antineoplastic chemotherapeutic agent a therapeutically effective amount of Nuclear Factor-kappa B (NF-κ
- B) inhibitor in conjunction with the administration of a dosage of the chemotherapeutic agent, whereby the cytotoxic effect of said antineoplastic chemotherapeutic agent is increased compared to that which would occur in the absence of NF-κ
B inhibitor;wherein the dosage of said antineoplastic chemotherapeutic agent is decreased as compared to a dosage effective without administering the NF-κ
B inhibitor in conjunction with the administration of the chemotherapeutic agent,and wherein said subject is afflicted with lung, breast, prostate, brain, kidney, liver, spleen, pancreas, bone or muscle cancer, leukemia or lymphoma, a sarcoma, a carcinoma or a mixed tumor. - View Dependent Claims (2, 3, 4, 5, 6, 7, 15, 16, 17, 18, 19, 20, 21, 22)
- B) inhibitor in conjunction with the administration of a dosage of the chemotherapeutic agent, whereby the cytotoxic effect of said antineoplastic chemotherapeutic agent is increased compared to that which would occur in the absence of NF-κ
-
8. The method of enhancing the cytotoxic effects of an antineoplastic chemotherapeutic agent, comprising administering to a mammalian subject in need of said antineoplastic chemotherapeutic agent a therapeutically effective amount of Nuclear Factor-kappa B (NF-κ
- B) inhibitor in conjunction with the administration of a dosage of the chemotherapeutic agent, whereby the cytotoxic effect of said antineoplastic chemotherapeutic agent is increased compared to that which would occur in the absence of NF-κ
B inhibitor;wherein the dosage of said antineoplastic chemotherapeutic agent is decreased as compared to a dosage effective without administering the NF-κ
B inhibitor in conjunction with the administration of the chemotherapeutic agent,wherein said NF-κ
B inhibitor is selected from the group consisting of;
a proteasome inhibitor, an inhibitor of ubiquitin conjugation, an inhibitor of proteasome peptidases, and a protease inhibitor. - View Dependent Claims (9, 10, 11, 12, 13, 14)
- B) inhibitor in conjunction with the administration of a dosage of the chemotherapeutic agent, whereby the cytotoxic effect of said antineoplastic chemotherapeutic agent is increased compared to that which would occur in the absence of NF-κ
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeUniversity of North Carolina At Chapel Hill (University of North Carolina System)
-
Original AssigneeUniversity of North Carolina At Chapel Hill (University of North Carolina System)
-
InventorsBaldwin, Albert S., Mayo, Marty W., Wang, Cun-Yu, Cusack, James C.
-
Primary Examiner(s)Kosar; Andrew D
-
Application NumberUS11/535,720Publication NumberTime in Patent Office1,301 DaysField of SearchNoneUS Class Current514/19.3CPC Class CodesA61K 2300/00 Mixtures or combinations of...A61K 31/4745 condensed with ring systems...A61K 31/70 Carbohydrates; Sugars; Deri...A61K 38/1709 from mammalsA61K 38/191 Tumor necrosis factors [TNF...
